Pilot Study of APD209 in Cancer Cachexia
To assess the efficacy of APD209 in adult patients with active cachexia associated with advanced malignancy and not caused by simple starvation.
To assess the safety of APD209 in patients with advanced malignancy and active cachexia.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of APD209 in Patients With Cachexia and Advanced Malignancy|
- Muscle size and function [ Time Frame: 8 weeks ]
|Study Start Date:||March 2009|
|Study Completion Date:||January 2012|
|Primary Completion Date:||November 2011 (Final data collection date for primary outcome measure)|
Oral tablets twice per day for 56 days
Please refer to this study by its ClinicalTrials.gov identifier: NCT00895726
|Royal Infirmary Edinburgh|
|Edinburgh, United Kingdom|
|Study Director:||Gabriel Fox, MB BChir||Acacia Pharma Ltd|